Form 4: Ginkgo Bioworks Director Sells $220K in Stock

Ginkgo Bioworks Holdings, Inc. Director Christian O. Henry sold 20,000 shares of Class A Common Stock over two days in early September 2025.

Summary

• Christian O. Henry, a Director of Ginkgo Bioworks Holdings, Inc. (DNA), reported the sale of 20,000 shares of Class A Common Stock.
• On September 8, 2025, Mr. Henry sold 10,000 shares at a weighted average price of $10.92 per share, totaling approximately $109,200.
• On September 9, 2025, an additional 10,000 shares were sold at a weighted average price of $11.06 per share, totaling approximately $110,600.
• The sales were conducted under a Rule 10b5-1(c) pre-arranged trading plan, indicating they were not based on new, material non-public information.
• Following these transactions, Mr. Henry directly beneficially owns 24,310 shares of Class A Common Stock.

Sentiment

Score: 4

Explanation: The filing reports insider selling by a director, which can be perceived negatively. However, the transactions were conducted under a pre-arranged 10b5-1 plan, mitigating the immediate negative signal.

Negatives

• A director's sale of shares, even if pre-planned, reduces insider ownership and can be perceived as a negative signal by the market.

Stakeholder Impact

• Shareholders may interpret the director's sale as a slight negative signal, potentially impacting investor confidence due to reduced insider alignment.

Key Dates

Recommendation

While a director's sale of shares can be perceived negatively, the transactions were executed under a pre-arranged 10b5-1 plan, suggesting the sales were not based on new, material non-public information. This mitigates the immediate negative signal, warranting a 'hold' rather than a 'sell' recommendation based solely on this filing.

Keywords

Ginkgo Bioworks, DNA, Insider Sale, Form 4, Christian Henry, Director, Stock Transaction, Biotechnology, 10b5-1 Plan